Originally published in The Center for Biosimilars
Biosimilars have struggled to gain ground in the United States, with few products launched, relatively low uptake of commercially available products, formulary restrictions that sometimes favor branded biologics over biosimilar options, and exclusionary contracting practices that block biosimilars from formularies altogether.
A variety of policy proposals have been put forward to help spur the US uptake of biosimilars, from legislative solutions to regulatory changes, but some providers are taking the matter into their own hands with concerted efforts to bring biosimilars to the clinic.
In an editorial appearing at the Articularis Health Group’s (AHG) website, Colin C. Edgerton, MD, one of the founding members of the rheumatology practice, explained that AHG has created a value-based rheumatoid arthritis (RA) treatment pathway that has boosted biosimilar use.
